This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bouizar, Z. Articles by Jullienne, A. Search for Related Content PubMed PubMed Citation Articles by Bouizar, Z. Articles by Jullienne, A.

Polymerase Chain Reaction Analysis of Parathyroid Hormone-related Protein Gene Expression in Breast Cancer Patients and Occurrence of Bone Metastases¹

Inserm U 349, Centre Viggo Petersen, Hôpital Lariboisiere, Paris [Z. B, M. C. V., A. J.], and Centre René Huguenin, Saint Cloud [F. S., S. D.], France

Parathyroid hormone-related protein (PTHrP) is associated with the syndrome of humoral hypercalcemia of malignancy. A high incidence of positive staining for PTHrP is observed in breast cancer and positivity is more frequent in patients who develop bone metastases. We assessed the presence of PTHrP mRNA by using the polymerase chain reaction in 38 normocalcemic breast cancer patients with long-term follow-up (minimum, 5 years) selected for the presence or absence of later bone metastasis development. In all the patients except one, the PTHrP gene was expressed in the breast tumor. The level of amplified PTHrP complementary DNA was inversely related to age (P < 0.02) and positively related to the proportion of invaded nodes (P < 0.02) but was not related to the other usual prognostic factors. The level of PTHrP mRNA was not different between the group of patients without recurrence or metastases (n = 11) and the group of patients who later developed metastases in soft tissues (n = 10). By contrast, patients who subsequently developed bone metastases (n = 17) showed higher PTHrP gene expression than patients in the other two groups (P < 0.001). This study suggests that strong PTHrP gene expression in breast tumors is associated with the onset of bone metastases.

¹ Supported by the Federation Nationale des Gefluc and by Grant 6954 from the Association pour la Recherche sur le Cancer.

² To whom requests for reprints should be addressed, at Inserm U 349, Centre Viggo Petersen, Hospital Lariboisiere, 6 Rue Guy Patin, 75010 Paris, France.

Received 7/ 6/93. Accepted 9/20/93.

This article has been cited by other articles:

				A. Sasaki, K. Ishikawa, N. Haraguchi, H. Inoue, T. Ishio, K. Shibata, M. Ohta, S. Kitano, and M. Mori Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis Ann. Surg. Oncol., March 1, 2007; 14(3): 1191 - 1199. [Abstract] [Full Text] [PDF]

				A. H. Gordon, R. J. O'Keefe, E. M. Schwarz, R. N. Rosier, and J. E. Puzas Nuclear Factor-{kappa}B-Dependent Mechanisms in Breast Cancer Cells Regulate Tumor Burden and Osteolysis in Bone Cancer Res., April 15, 2005; 65(8): 3209 - 3217. [Abstract] [Full Text] [PDF]

				M. A. Henderson, J. A. Danks, J. M. Moseley, J. L. Slavin, T. L. Harris, M. R. McKinlay, J. L. Hopper, and T. J. Martin Parathyroid Hormone-Related Protein Production by Breast Cancers, Improved Survival, and Reduced Bone Metastases J Natl Cancer Inst, February 7, 2001; 93(3): 234 - 237. [Full Text] [PDF]

				Y. Nishigaki, Y. Ohsaki, E. Toyoshima, and K. Kikuchi Increased Serum and Urinary Levels of a Parathyroid Hormone-related Protein COOH Terminus in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., June 1, 1999; 5(6): 1473 - 1481. [Abstract] [Full Text] [PDF]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]